{"protocolSection":{"identificationModule":{"nctId":"NCT03195491","orgStudyIdInfo":{"id":"CA209-870"},"organization":{"fullName":"Bristol-Myers Squibb","class":"INDUSTRY"},"briefTitle":"A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia","officialTitle":"An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia","acronym":"CheckMate870"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2017-12-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2021-06-08","type":"ACTUAL"},"completionDateStruct":{"date":"2021-06-08","type":"ACTUAL"},"studyFirstSubmitDate":"2017-06-20","studyFirstSubmitQcDate":"2017-06-20","studyFirstPostDateStruct":{"date":"2017-06-22","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-06-08","resultsFirstSubmitQcDate":"2024-01-26","resultsFirstPostDateStruct":{"date":"2024-07-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-26","lastUpdatePostDateStruct":{"date":"2024-07-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Bristol-Myers Squibb","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment."},"conditionsModule":{"conditions":["Lung Cancer","Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":400,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Monotherapy","type":"EXPERIMENTAL","description":"Nivolumab administered every two weeks","interventionNames":["Biological: Nivolumab"]}],"interventions":[{"type":"BIOLOGICAL","name":"Nivolumab","description":"Intravenous infusion administered over 30 minutes at 240 mg","armGroupLabels":["Monotherapy"],"otherNames":["Opdivo","BMS-936558"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events","description":"Number of non-HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in non-HBV infected participants. To evaluate safety and tolerability in non-HBV infected participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed during or after one prior systemic therapy and are treated with nivolumab monotherapy with an infusion duration of 30 minutes. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.","timeFrame":"From first dose up to 100 days post dose, up to approximately 36 months"}],"secondaryOutcomes":[{"measure":"Number of HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events","description":"Number of HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in HBV participants. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.","timeFrame":"From first dose up to 100 days post dose, up to approximately 36 months"},{"measure":"Number of Participants Experiencing Adverse Events (AEs)","description":"An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.","timeFrame":"From first dose up to 100 days post dose, up to approximately 36 months"},{"measure":"Overall Survival (OS)","description":"Overall survival (OS) is defined as the time from the first dosing date to the date of death. Participants without documentation of death will be recorded on the last date the participant was known to be alive. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).","timeFrame":"From the first dose up to the date of death. Participants without documentation of death will be censored on the late date known to be alive, up to approximately 32 months"},{"measure":"Progression-Free Survival (PFS)","description":"PFS is the time from first dose to the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who die without a reported prior progression are considered to have progressed on their death date. Participants who did not progress or die will be documented on the date of their last evaluable tumor assessment. Participants who did not have any on study tumor assessments and did not die will be documented on their first dose date. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be documented at the last evaluable tumor assessment prior to initiation of the subsequent anti-cancer therapy. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC). Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","timeFrame":"From the first dose up to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause, up to approximately 30 months"},{"measure":"Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests","description":"Number of Participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria","timeFrame":"From first dose up to 100 days post last dose, up to approximately 36 months"},{"measure":"Number of Participants Experiencing Serious Adverse Events (SAEs)","description":"Number of Participants experiencing SAEs are tabulated using worst grade per NCI CTCAE v.4 criteria by system organ class and MedDRA preferred term.","timeFrame":"From first dose to 100 days post last dose, up to 36 months"},{"measure":"Objective Response Rate","description":"Objective Response Rate (ORR) is defined as the percentage of all treated subjects whose best overall response (BOR) from baseline is either a CR or PR per RECIST 1.1 criteria. BOR is determined by the best response designation recorded between the first dose date and the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. For subjects without documented progression or subsequent anticancer therapy, all available response designations will contribute to the BOR determination. For subjects who continue nivolumab beyond progression, the BOR should be determined based on response designations recorded at the time of the initial RECIST 1.1 defined progression.","timeFrame":"From the first dose date up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. Up to approximately 36 months"},{"measure":"Duration of Tumor Response","description":"Duration of Response (DOR) is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who neither progress nor die will be documented on the date of their last assessment. The censoring algorithm for DOR will be the same as used for PFS definition. This endpoint will only be evaluated for participants with the best overall response of complete response or partial response.","timeFrame":"From the date of first confirmed response to the date of the first documented tumor progression, up to approximately 30 months"},{"measure":"Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests","description":"Number of participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria","timeFrame":"From randomization to 100 days post last dose, up to 36 months"},{"measure":"Time to Treatment Failure (TTF)","description":"Time to Treatment Failure is defined as the minimum of the time from treatment assignment to disease progression (determined by investigator assessments using RECIST 1.1), death or last dose date if a participant progressed, died or discontinued from treatment for any reasons other than \"maximum clinical benefit\" and \"administrative reasons by sponsor\". TTF is censored at the last dose date for participants who continued on treatment without progression (per RECIST 1.1) or death at the time of the database lock. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).","timeFrame":"From treatment assignment to disease progression, death or last dose date, up to approximately 16 months"}]},"eligibilityModule":{"eligibilityCriteria":"For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com\n\nInclusion Criteria:\n\n* Advanced metastatic stage IIIB/IV NSCLC (Nonsquamous and squamous)\n* 1 to 2 prior systemic therapies\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 1\n* Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI)\n* Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to starting study treatment\n\nExclusion Criteria:\n\n* Women with a positive pregnancy test at enrollment or prior to administration of study medication\n* Participants with active central nervous system metastases\n* Participants with a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first dose of study drug\n* Participants with previous malignancies are excluded unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required or anticipated to be required during the study period\n* Participants with carcinomatous meningitis\n\nOther protocol defined inclusion/exclusion criteria could apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Bristol-Myers Squibb","affiliation":"Bristol-Myers Squibb","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Local Institution","city":"Beijing","state":"Beijing Municipality","zip":"100001","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Local Institution","city":"Beijing","state":"Beijing Municipality","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Local Institution","city":"Beijing","state":"Beijing Municipality","zip":"100730","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Local Institution","city":"Beijing","state":"Beijing Municipality","zip":"101149","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Local Institution","city":"Fuzhou","state":"Fujian","zip":"350014","country":"China","geoPoint":{"lat":26.06139,"lon":119.30611}},{"facility":"Local Institution","city":"Guangzhou","state":"Guangdong","zip":"510080","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Local Institution","city":"Beijingcun","state":"Hebei","zip":"100031","country":"China","geoPoint":{"lat":41.26103,"lon":119.10946}},{"facility":"Local Institution","city":"Harbin","state":"Heilongjiang","zip":"150081","country":"China","geoPoint":{"lat":45.75,"lon":126.65}},{"facility":"Local Institution","city":"Zhengzhou","state":"Henan","zip":"450008","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Local Institution","city":"Wuhan","state":"Hubei","zip":"430022","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Local Institution - 0017","city":"Changsha","state":"Hunan","zip":"410013","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Local Institution","city":"Nanjing","state":"Jiangsu","zip":"210002","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"Local Institution","city":"Nanjing","state":"Jiangsu","zip":"210008","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"Local Institution","city":"Changchun","state":"Jilin","zip":"130012","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Local Institution","city":"Changchun","state":"Jilin","zip":"130021","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"Local Institution","city":"Xi'an","state":"Shan3xi","zip":"710038","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"Local Institution","city":"Jinan","state":"Shandong","zip":"250031","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Local Institution","city":"Shanghai","state":"Shanghai Municipality","zip":"200025","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Local Institution","city":"Shanghai","state":"Shanghai Municipality","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Local Institution","city":"Tianjin","state":"Tianjin Municipality","zip":"300222","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"Local Institution","city":"Ürümqi","state":"Xinjiang","zip":"830011","country":"China","geoPoint":{"lat":43.80096,"lon":87.60046}},{"facility":"Local Institution","city":"Hangzhou","state":"Zhejiang","zip":"310000","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Local Institution","city":"Hangzhou","state":"Zhejiang","zip":"310003","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Local Institution","city":"Hangzhou","state":"Zhejiang","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Local Institution","city":"Guangzhou","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Local Institution","city":"Shanghai","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Local Institution","city":"Shanghai","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Local Institution","city":"Shenyang","zip":"110042","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Local Institution","city":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Local Institution","city":"Khon Kaen","zip":"40002","country":"Thailand","geoPoint":{"lat":16.44671,"lon":102.833}}]},"referencesModule":{"seeAlsoLinks":[{"label":"BMS Clinical Trial Information","url":"https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html"},{"label":"BMS Clinical Trial Patient Recruiting","url":"https://www.bmsstudyconnect.com/s/US/English/USenHome"},{"label":"Investigator Inquiry Form","url":"https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html"},{"label":"FDA Safety Alerts and Recalls","url":"https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"FG001","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"383"},{"groupId":"FG001","numSubjects":"17"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"347"},{"groupId":"FG001","numSubjects":"15"}]}],"dropWithdraws":[{"type":"Study drug toxicity","reasons":[{"groupId":"FG000","numSubjects":"25"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Maximum clinical benefit","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Adverse event unrelated to study drug","reasons":[{"groupId":"FG000","numSubjects":"19"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Disease progression","reasons":[{"groupId":"FG000","numSubjects":"266"},{"groupId":"FG001","numSubjects":"8"}]},{"type":"Other reasons","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Participant withdrew consent","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Participant no longer meets study criteria","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Participant request to discontinue study treatment","reasons":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All treated participants","groups":[{"id":"BG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"BG001","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"383"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"400"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.6","spread":"8.72"},{"groupId":"BG001","value":"59.1","spread":"7.86"},{"groupId":"BG002","value":"60.5","spread":"8.68"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"86"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"301"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"314"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Chinese","categories":[{"measurements":[{"groupId":"BG000","value":"377"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"394"}]}]},{"title":"Asian Other","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"6"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Non-HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events","description":"Number of non-HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in non-HBV infected participants. To evaluate safety and tolerability in non-HBV infected participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed during or after one prior systemic therapy and are treated with nivolumab monotherapy with an infusion duration of 30 minutes. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.","populationDescription":"All treated non-HBV infected participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose up to 100 days post dose, up to approximately 36 months","groups":[{"id":"OG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"}]}],"classes":[{"title":"Gastrointestinal Adverse","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Hepatic Adverse Event","categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]},{"title":"Pulmonary Adverse Event","categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]},{"title":"Renal Adverse Event","categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]},{"title":"Skin Adverse Event","categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}]},{"type":"SECONDARY","title":"Number of HBV Participants Experiencing High Grade Treatment-Related Select Adverse Events","description":"Number of HBV participants experiencing high grade (combined CTCAE v4 Grade 3-4 and Grade 5) treatment-related select adverse events in HBV participants. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.","populationDescription":"All treated HBV infected participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose up to 100 days post dose, up to approximately 36 months","groups":[{"id":"OG000","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"}]}],"classes":[{"title":"Gastrointestinal Adverse Event","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Hepatic Adverse Event","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Pulmonary Adverse Event","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Renal Adverse Event","categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]},{"title":"Skin Adverse Reaction","categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Adverse Events (AEs)","description":"An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal.","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose up to 100 days post dose, up to approximately 36 months","groups":[{"id":"OG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG001","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"17"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) is defined as the time from the first dosing date to the date of death. Participants without documentation of death will be recorded on the last date the participant was known to be alive. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).","populationDescription":"This is a single arm trial with two enrollment cohorts, HPV positive and HPV negative. All participants received the same treatment. Due to the small number of participants in the HPV cohorts, it is not meaningful to perform additional subgroup analysis. For example, there were only 17 participants in the HPV positive cohort, which is less than 5% (17/400 = 4.25%) from the overall. Therefore, all additional efficacy subgroup analysis was performed based on all treated participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From the first dose up to the date of death. Participants without documentation of death will be censored on the late date known to be alive, up to approximately 32 months","groups":[{"id":"OG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG001","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG002","title":"All Treated Participants","description":"All treated participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"400"}]}],"classes":[{"title":"All treated participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"400"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.16","lowerLimit":"12.25","upperLimit":"18.07"},{"groupId":"OG001","value":"22.31","lowerLimit":"10.02","upperLimit":"NA","comment":"Upper limit not calculated due to insufficient number of events."},{"groupId":"OG002","value":"14.65","lowerLimit":"12.32","upperLimit":"18.10"}]}]},{"title":"PD-L1 < 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"174"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"13.31","lowerLimit":"10.87","upperLimit":"17.71"}]}]},{"title":"PD-L1 ≥ 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"168"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"19.25","lowerLimit":"12.94","upperLimit":"23.46"}]}]},{"title":"PD-L1 < 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"205"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"14.65","lowerLimit":"11.63","upperLimit":"18.10"}]}]},{"title":"PD-L1 ≥ 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"18.37","lowerLimit":"11.70","upperLimit":"22.77"}]}]},{"title":"PD-L1 < 10%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"14.72","lowerLimit":"12.35","upperLimit":"18.76"}]}]},{"title":"PD-L1 ≥ 10%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"17.68","lowerLimit":"10.78","upperLimit":"21.03"}]}]},{"title":"PD-L1 < 50%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"272"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"16.23","lowerLimit":"12.52","upperLimit":"18.86"}]}]},{"title":"PD-L1 ≥ 50%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"14.75","lowerLimit":"10.68","upperLimit":"29.04"}]}]},{"title":"PD-L1 Not Reportable","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"11.99","lowerLimit":"9.17","upperLimit":"19.19"}]}]},{"title":"Squamous Tumor Histology","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"13.80","lowerLimit":"10.78","upperLimit":"18.37"}]}]},{"title":"Non-squamous Tumor Histology","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"264"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"14.75","lowerLimit":"11.70","upperLimit":"19.32"}]}]},{"title":"EGFR Mutation Positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"19.32","lowerLimit":"11.24","upperLimit":"31.74"}]}]},{"title":"ALK translocation positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"16.48","lowerLimit":"1.28","upperLimit":"NA","comment":"Upper limit not reached due to insufficient number of events."}]}]}]},{"type":"SECONDARY","title":"Progression-Free Survival (PFS)","description":"PFS is the time from first dose to the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who die without a reported prior progression are considered to have progressed on their death date. Participants who did not progress or die will be documented on the date of their last evaluable tumor assessment. Participants who did not have any on study tumor assessments and did not die will be documented on their first dose date. Participants who started any subsequent anti-cancer therapy without a prior reported progression will be documented at the last evaluable tumor assessment prior to initiation of the subsequent anti-cancer therapy. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC). Per RECIST v1.0 for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.","populationDescription":"This is a single arm trial with two enrollment cohorts, HPV positive and HPV negative. All participants received the same treatment. Due to the small number of participants in the HPV cohorts, it is not meaningful to perform additional subgroup analysis. For example, there were only 17 participants in the HPV positive cohort, which is less than 5% (17/400 = 4.25%) from the overall. Therefore, all additional efficacy subgroup analysis was performed based on all treated participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From the first dose up to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause, up to approximately 30 months","groups":[{"id":"OG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG001","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG002","title":"All Treated Participants","description":"All treated participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"400"}]}],"classes":[{"title":"All treated participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"400"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.61","lowerLimit":"2.33","upperLimit":"3.75"},{"groupId":"OG001","value":"2.04","lowerLimit":"1.64","upperLimit":"10.22"},{"groupId":"OG002","value":"3.61","lowerLimit":"2.33","upperLimit":"3.75"}]}]},{"title":"PD-L1 < 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"174"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"2.33","lowerLimit":"1.94","upperLimit":"3.68"}]}]},{"title":"PD-L1 ≥ 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"168"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"4.73","lowerLimit":"3.68","upperLimit":"5.65"}]}]},{"title":"PD-L1 < 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"205"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"2.37","lowerLimit":"1.94","upperLimit":"3.68"}]}]},{"title":"PD-L1 ≥ 5","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"5.42","lowerLimit":"3.68","upperLimit":"5.65"}]}]},{"title":"PD-L1 < 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"2.50","lowerLimit":"1.94","upperLimit":"3.68"}]}]},{"title":"PD-L1 ≥ 10","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"5.45","lowerLimit":"3.68","upperLimit":"5.65"}]}]},{"title":"PD-L1 < 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"272"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"3.58","lowerLimit":"2.07","upperLimit":"3.75"}]}]},{"title":"PD-L1 ≥ 50","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"5.55","lowerLimit":"2.23","upperLimit":"7.33"}]}]},{"title":"EGFR mutation positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"1.87","lowerLimit":"1.71","upperLimit":"4.73"}]}]},{"title":"ALK translocation positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"1.91","lowerLimit":"1.28","upperLimit":"16.36"}]}]},{"title":"Squamous subgroup","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"3.75","lowerLimit":"3.06","upperLimit":"5.55"}]}]},{"title":"Non-squamous subgroup","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"264"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"2.79","lowerLimit":"1.94","upperLimit":"3.68"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Laboratory Abnormalities in Specific Liver Tests","description":"Number of Participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose up to 100 days post last dose, up to approximately 36 months","groups":[{"id":"OG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG001","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"}]}],"classes":[{"title":"ALT OR AST > 3XULN","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"1"}]}]},{"title":"ALT OR AST > 5XULN","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"}]}]},{"title":"ALT OR AST > 10XULN","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"ALT OR AST > 20XULN","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"TOTAL BILIRUBIN > 2XULN","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN ONE DAY","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"CONCURRENT ALT OR AST ELEVATION > 3XULN WITH TOTAL BILIRUBIN > 2XULN WITHIN 30 DAY","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Serious Adverse Events (SAEs)","description":"Number of Participants experiencing SAEs are tabulated using worst grade per NCI CTCAE v.4 criteria by system organ class and MedDRA preferred term.","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From first dose to 100 days post last dose, up to 36 months","groups":[{"id":"OG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG001","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"12"}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate","description":"Objective Response Rate (ORR) is defined as the percentage of all treated subjects whose best overall response (BOR) from baseline is either a CR or PR per RECIST 1.1 criteria. BOR is determined by the best response designation recorded between the first dose date and the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. For subjects without documented progression or subsequent anticancer therapy, all available response designations will contribute to the BOR determination. For subjects who continue nivolumab beyond progression, the BOR should be determined based on response designations recorded at the time of the initial RECIST 1.1 defined progression.","populationDescription":"This is a single arm trial with two enrollment cohorts, HPV positive and HPV negative. All participants received the same treatment. Due to the small number of participants in the HPV cohorts, it is not meaningful to perform additional subgroup analysis. For example, there were only 17 participants in the HPV positive cohort, which is less than 5% (17/400 = 4.25%) from the overall. Therefore, all additional efficacy subgroup analysis was performed based on all treated participants.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"From the first dose date up to the date of objectively documented progression or the date of subsequent anti-cancer therapy, whichever occurs first. Up to approximately 36 months","groups":[{"id":"OG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG001","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG002","title":"All Treated Participants","description":"All treated participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"400"}]}],"classes":[{"title":"All treated participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"400"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.88","lowerLimit":"11.47","upperLimit":"18.85"},{"groupId":"OG001","value":"17.65","lowerLimit":"3.80","upperLimit":"43.43"},{"groupId":"OG002","value":"15.00","lowerLimit":"11.65","upperLimit":"18.88"}]}]},{"title":"Squamous tumor histology","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"18.38","lowerLimit":"12.26","upperLimit":"25.93"}]}]},{"title":"Non-squamous tumor histology","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"264"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"13.26","lowerLimit":"9.41","upperLimit":"17.95"}]}]},{"title":"PD-L1 < 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"174"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"6.32","lowerLimit":"3.20","upperLimit":"11.03"}]}]},{"title":"PD-L1 ≥ 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"168"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"25.60","lowerLimit":"19.18","upperLimit":"32.89"}]}]},{"title":"PD-L1 < 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"205"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"8.78","lowerLimit":"5.29","upperLimit":"13.52"}]}]},{"title":"PD-L1 ≥ 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"26.28","lowerLimit":"19.13","upperLimit":"34.48"}]}]},{"title":"PD-L1 < 10%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"10.81","lowerLimit":"7.05","upperLimit":"15.66"}]}]},{"title":"PD-L1 ≥ 10%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"25.00","lowerLimit":"17.55","upperLimit":"33.73"}]}]},{"title":"PD-L1 < 50%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"272"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"11.76","lowerLimit":"8.19","upperLimit":"16.20"}]}]},{"title":"PD-L1 ≥ 50%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"31.43","lowerLimit":"20.85","upperLimit":"43.63"}]}]},{"title":"EGFR mutation positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"17.65","lowerLimit":"6.76","upperLimit":"34.53"}]}]},{"title":"ALK translocation positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"10.00","lowerLimit":"0.25","upperLimit":"44.50"}]}]}]},{"type":"SECONDARY","title":"Duration of Tumor Response","description":"Duration of Response (DOR) is defined as the time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who neither progress nor die will be documented on the date of their last assessment. The censoring algorithm for DOR will be the same as used for PFS definition. This endpoint will only be evaluated for participants with the best overall response of complete response or partial response.","populationDescription":"This is a single arm trial with two enrollment cohorts, HPV positive and HPV negative. All participants received the same treatment. Due to the small number of participants in the HPV cohorts, it is not meaningful to perform additional subgroup analysis. For example, there were only 17 participants in the HPV positive cohort, which is less than 5% (17/400 = 4.25%) from the overall. Therefore, all additional efficacy subgroup analysis was performed based on all treated participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From the date of first confirmed response to the date of the first documented tumor progression, up to approximately 30 months","groups":[{"id":"OG000","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG001","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG002","title":"All Treated Participants","description":"All treated participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"60"}]}],"classes":[{"title":"All treated participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"60"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"8.15","upperLimit":"NA","comment":"Median and upper limit not reached due to insufficient number of events."},{"groupId":"OG001","value":"19.38","lowerLimit":"11.04","upperLimit":"24.97"},{"groupId":"OG002","value":"19.38","lowerLimit":"11.04","upperLimit":"24.97"}]}]},{"title":"Squamous tumor histology","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"25"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"12.62","lowerLimit":"8.11","upperLimit":"25.33"}]}]},{"title":"Non-squamous tumor histology","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"19.61","lowerLimit":"9.49","upperLimit":"27.60"}]}]},{"title":"PD-L1 < 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"19.38","lowerLimit":"8.11","upperLimit":"24.97"}]}]},{"title":"PD-L1 ≥ 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"42"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"16.11","lowerLimit":"9.43","upperLimit":"27.60"}]}]},{"title":"PD-L1 < 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"17"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"19.38","lowerLimit":"8.11","upperLimit":"24.97"}]}]},{"title":"PD-L1 ≥ 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"19.61","lowerLimit":"9.33","upperLimit":"29.70"}]}]},{"title":"PD-L1 < 10%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"12.06","lowerLimit":"8.11","upperLimit":"24.97"}]}]},{"title":"PD-L1 ≥ 10%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"21.13","lowerLimit":"9.43","upperLimit":"NA","comment":"Upper limit not reached due to insufficient number of events."}]}]},{"title":"PD-L1 < 50%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"31"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"12.06","lowerLimit":"8.15","upperLimit":"24.97"}]}]},{"title":"PD-L1 ≥ 50%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"21.49","lowerLimit":"9.30","upperLimit":"NA","comment":"Upper limit not reached due to insufficient number of events."}]}]},{"title":"EGFR mutation positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"12.57","lowerLimit":"5.59","upperLimit":"NA","comment":"Upper limit not reached due to insufficient number of events."}]}]},{"title":"ALK translocation positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"19.42","lowerLimit":"NA","upperLimit":"NA","comment":"Lower and upper limits not reached due to insufficient number of events."}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Laboratory Abnormalities in Specific Thyroid Tests","description":"Number of participants experiencing laboratory abnormalities are defined as on-study lab parameters summarized by using the worst grade per NCI CTCAE v.4 criteria","populationDescription":"All treated participants","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From randomization to 100 days post last dose, up to 36 months","groups":[{"id":"OG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG001","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"}]}],"classes":[{"title":"TSH > ULN","categories":[{"measurements":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"1"}]}]},{"title":"TSH > ULN WITH TSH <= ULN AT BASELINE","categories":[{"measurements":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"0"}]}]},{"title":"TSH > ULN WITH AT LEAST ONE FT3/FT4 TEST VALUE < LLN","categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"1"}]}]},{"title":"TSH > ULN WITH ALL OTHER FT3/FT4 TEST VALUES >= LLN","categories":[{"measurements":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"0"}]}]},{"title":"TSH > ULN WITH FT3/FT4 TEST MISSING","categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"1"}]}]},{"title":"TSH < LLN","categories":[{"measurements":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"3"}]}]},{"title":"TSH < LLN WITH TSH >= LLN AT BASELINE","categories":[{"measurements":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"3"}]}]},{"title":"TSH < LLN WITH AT LEAST ONE FT3/FT4 TEST VALUE > ULN","categories":[{"measurements":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"1"}]}]},{"title":"TSH < LLN WITH ALL OTHER FT3/FT4 TEST VALUES <= ULN","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"2"}]}]},{"title":"TSH < LLN WITH FT3/FT4 TEST MISSING","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"2"}]}]}]},{"type":"SECONDARY","title":"Time to Treatment Failure (TTF)","description":"Time to Treatment Failure is defined as the minimum of the time from treatment assignment to disease progression (determined by investigator assessments using RECIST 1.1), death or last dose date if a participant progressed, died or discontinued from treatment for any reasons other than \"maximum clinical benefit\" and \"administrative reasons by sponsor\". TTF is censored at the last dose date for participants who continued on treatment without progression (per RECIST 1.1) or death at the time of the database lock. Tumor PD-L1 protein expression was measured by immunohistochemistry (IHC).","populationDescription":"This is a single arm trial with two enrollment cohorts, HPV positive and HPV negative. All participants received the same treatment. Due to the small number of participants in the HPV cohorts, it is not meaningful to perform additional subgroup analysis. For example, there were only 17 participants in the HPV positive cohort, which is less than 5% (17/400 = 4.25%) from the overall. Therefore, all additional efficacy subgroup analysis was performed based on all treated participants.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"From treatment assignment to disease progression, death or last dose date, up to approximately 16 months","groups":[{"id":"OG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG001","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."},{"id":"OG002","title":"All Treated Participants","description":"All treated participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"400"}]}],"classes":[{"title":"All treated participants","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"383"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"400"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.23","lowerLimit":"1.94","upperLimit":"3.52"},{"groupId":"OG001","value":"1.97","lowerLimit":"1.41","upperLimit":"10.22"},{"groupId":"OG002","value":"2.10","lowerLimit":"1.94","upperLimit":"3.52"}]}]},{"title":"Squamous Tumor Histology","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"136"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"3.68","lowerLimit":"2.10","upperLimit":"5.45"}]}]},{"title":"Non-Squamous Tumor Histology","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"264"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"1.94","lowerLimit":"1.87","upperLimit":"2.50"}]}]},{"title":"EGFR Mutation Positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"1.86","lowerLimit":"1.68","upperLimit":"3.65"}]}]},{"title":"ALK Translocation Positive","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"1.91","lowerLimit":"1.28","upperLimit":"16.36"}]}]},{"title":"PD-L1 < 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"174"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"1.97","lowerLimit":"1.87","upperLimit":"2.92"}]}]},{"title":"PD-L1 ≥ 1%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"168"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"3.68","lowerLimit":"2.17","upperLimit":"5.55"}]}]},{"title":"PD-L1 < 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"205"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"1.97","lowerLimit":"1.87","upperLimit":"3.06"}]}]},{"title":"PD-L1 ≥ 5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"137"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"3.68","lowerLimit":"2.23","upperLimit":"5.55"}]}]},{"title":"PD-L1 < 10%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"222"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"1.97","lowerLimit":"1.87","upperLimit":"3.09"}]}]},{"title":"PD-L1 ≥ 10%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"3.75","lowerLimit":"2.23","upperLimit":"5.55"}]}]},{"title":"PD-L1 < 50%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"272"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"2.14","lowerLimit":"1.91","upperLimit":"3.58"}]}]},{"title":"PD-L1 ≥ 50%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"70"}]}],"categories":[{"measurements":[{"groupId":"OG002","value":"4.11","lowerLimit":"2.00","upperLimit":"6.01"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"All-cause mortality was assessed from date of first dose to study completion (up to approximately 41 months). Serious Adverse events and other adverse events were assessed from date of first dose to 100 days following date of last dose (up to approximately 36 months).","eventGroups":[{"id":"EG000","title":"Non-HBV Participants","description":"Non-Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year.","deathsNumAffected":270,"deathsNumAtRisk":383,"seriousNumAffected":157,"seriousNumAtRisk":383,"otherNumAffected":359,"otherNumAtRisk":383},{"id":"EG001","title":"HBV Participants","description":"Hepatitis B Virus (HBV) participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year.","deathsNumAffected":9,"deathsNumAtRisk":17,"seriousNumAffected":12,"seriousNumAtRisk":17,"otherNumAffected":17,"otherNumAtRisk":17},{"id":"EG002","title":"TOTAL","description":"All treated participants who received Nivolumab 240 mg monotherapy/30 minute IV infusion every 2 weeks. Treatment will be given up to 24 months in the absence of disease progression or unacceptable toxicity. Treatment with nivolumab could be reinitiated as per the initial schedule for subsequent disease progression and administered for up to 1 additional year.","deathsNumAffected":279,"deathsNumAtRisk":400,"seriousNumAffected":169,"seriousNumAtRisk":400,"otherNumAffected":376,"otherNumAtRisk":400}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Immune-mediated myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Sinus bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Ventricular fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Ascites","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":400}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Oesophageal obstruction","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":400}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Multiple organ dysfunction syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":400}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Drug-induced liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Hepatic function abnormal","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":5,"numAtRisk":400}]},{"term":"Liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Contrast media allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Endophthalmitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Lymphangitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":383},{"groupId":"EG001","numAffected":4,"numAtRisk":17},{"groupId":"EG002","numAffected":33,"numAtRisk":400}]},{"term":"Pulmonary tuberculosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Soft tissue infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":400}]},{"term":"Lumbar vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":400}]},{"term":"Troponin I increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Diabetic ketoacidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":400}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Benign neoplasm of skin","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Bladder cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Colon cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Lung adenocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Lung cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Malignant neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":19,"numAtRisk":400}]},{"term":"Metastases to bone","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Metastases to central nervous system","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":400}]},{"term":"Metastases to spine","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Neoplasm progression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Neuroendocrine carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Non-small cell lung cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Rectal cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Altered state of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Ataxia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":400}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Lacunar infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Vascular headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Atelectasis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Bronchial obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Choking","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":8,"numAtRisk":400}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":12,"numAtRisk":400}]},{"term":"Hydrothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Hypoxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":9,"numAtRisk":400}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":10,"numAtRisk":400}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":400}]},{"term":"Tracheal fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Erythema multiforme","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":155,"numAtRisk":383},{"groupId":"EG001","numAffected":7,"numAtRisk":17},{"groupId":"EG002","numAffected":162,"numAtRisk":400}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":383},{"groupId":"EG001","numAffected":4,"numAtRisk":17},{"groupId":"EG002","numAffected":25,"numAtRisk":400}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":28,"numAtRisk":400}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":48,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":49,"numAtRisk":400}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":39,"numAtRisk":383},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":42,"numAtRisk":400}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":28,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":30,"numAtRisk":400}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":42,"numAtRisk":400}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":28,"numAtRisk":400}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":383},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":36,"numAtRisk":400}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":383},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":21,"numAtRisk":400}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":60,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":62,"numAtRisk":400}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":50,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":52,"numAtRisk":400}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":27,"numAtRisk":400}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":72,"numAtRisk":383},{"groupId":"EG001","numAffected":6,"numAtRisk":17},{"groupId":"EG002","numAffected":78,"numAtRisk":400}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":383},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":44,"numAtRisk":400}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":383},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":40,"numAtRisk":400}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":62,"numAtRisk":383},{"groupId":"EG001","numAffected":4,"numAtRisk":17},{"groupId":"EG002","numAffected":66,"numAtRisk":400}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":59,"numAtRisk":383},{"groupId":"EG001","numAffected":5,"numAtRisk":17},{"groupId":"EG002","numAffected":64,"numAtRisk":400}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":21,"numAtRisk":400}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":23,"numAtRisk":400}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":23,"numAtRisk":400}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":26,"numAtRisk":400}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":21,"numAtRisk":400}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":30,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":30,"numAtRisk":400}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":21,"numAtRisk":400}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":22,"numAtRisk":400}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":66,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":67,"numAtRisk":400}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":23,"numAtRisk":400}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":94,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":96,"numAtRisk":400}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":32,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":33,"numAtRisk":400}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":46,"numAtRisk":383},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":49,"numAtRisk":400}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":22,"numAtRisk":400}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":43,"numAtRisk":400}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":383},{"groupId":"EG001","numAffected":6,"numAtRisk":17},{"groupId":"EG002","numAffected":58,"numAtRisk":400}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":27,"numAtRisk":400}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":30,"numAtRisk":400}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":34,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":34,"numAtRisk":400}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":21,"numAtRisk":400}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":26,"numAtRisk":400}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":85,"numAtRisk":383},{"groupId":"EG001","numAffected":7,"numAtRisk":17},{"groupId":"EG002","numAffected":92,"numAtRisk":400}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":48,"numAtRisk":383},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":51,"numAtRisk":400}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":37,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":37,"numAtRisk":400}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":49,"numAtRisk":383},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":52,"numAtRisk":400}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":50,"numAtRisk":383},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":53,"numAtRisk":400}]},{"term":"Granulocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":10,"numAtRisk":400}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":5,"numAtRisk":400}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":5,"numAtRisk":400}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":400}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":7,"numAtRisk":400}]},{"term":"Dry eye","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":11,"numAtRisk":400}]},{"term":"Abdominal pain lower","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":400}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":10,"numAtRisk":400}]},{"term":"Chronic gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":400}]},{"term":"Gingival pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":400}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":10,"numAtRisk":400}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":18,"numAtRisk":400}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":7,"numAtRisk":400}]},{"term":"Liver injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":7,"numAtRisk":400}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":5,"numAtRisk":400}]},{"term":"Hepatitis C","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Tooth infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":12,"numAtRisk":400}]},{"term":"Eye injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Procedural pain","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":7,"numAtRisk":400}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":9,"numAtRisk":400}]},{"term":"Blood phosphorus decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":5,"numAtRisk":400}]},{"term":"Blood uric acid decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":10,"numAtRisk":400}]},{"term":"Brain natriuretic peptide increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":400}]},{"term":"C-reactive protein increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":7,"numAtRisk":400}]},{"term":"Carcinoembryonic antigen increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Gastric pH decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":400}]},{"term":"Hepatitis B DNA increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Neutrophil count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":383},{"groupId":"EG001","numAffected":4,"numAtRisk":17},{"groupId":"EG002","numAffected":19,"numAtRisk":400}]},{"term":"Neutrophil percentage increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Procalcitonin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Red blood cell sedimentation rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Tri-iodothyronine free increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":6,"numAtRisk":400}]},{"term":"Volume blood decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":383},{"groupId":"EG001","numAffected":0,"numAtRisk":17},{"groupId":"EG002","numAffected":20,"numAtRisk":400}]},{"term":"Acidosis","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":8,"numAtRisk":400}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":400}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":8,"numAtRisk":400}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":19,"numAtRisk":400}]},{"term":"Hypochloraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":17,"numAtRisk":400}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":6,"numAtRisk":400}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":10,"numAtRisk":400}]},{"term":"Tetany","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":8,"numAtRisk":400}]},{"term":"Flank pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":7,"numAtRisk":400}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":383},{"groupId":"EG001","numAffected":3,"numAtRisk":17},{"groupId":"EG002","numAffected":17,"numAtRisk":400}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":18,"numAtRisk":400}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":2,"numAtRisk":400}]},{"term":"Trigeminal neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Bronchial haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":400}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":6,"numAtRisk":400}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":7,"numAtRisk":400}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":400}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":3,"numAtRisk":400}]},{"term":"Sputum discoloured","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":400}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":1,"numAtRisk":400}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":383},{"groupId":"EG001","numAffected":1,"numAtRisk":17},{"groupId":"EG002","numAffected":4,"numAtRisk":400}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":18,"numAtRisk":400}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 24.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":383},{"groupId":"EG001","numAffected":2,"numAtRisk":17},{"groupId":"EG002","numAffected":14,"numAtRisk":400}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."},"pointOfContact":{"title":"Bristol-Myers Squibb Study Director","organization":"Bristol-Myers Squibb","email":"Clinical.Trials@bms.com","phone":"Please email"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2017-10-25","uploadDate":"2022-06-08T09:56","filename":"Prot_000.pdf","size":920472},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-05-16","uploadDate":"2023-03-28T14:35","filename":"SAP_001.pdf","size":1055638}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["France","United States"]},"conditionBrowseModule":{"meshes":[{"id":"D008175","term":"Lung Neoplasms"},{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077594","term":"Nivolumab"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"}]}},"hasResults":true}